Med2Date — Clinical Guidelines
Home Immunology Inherited Deficiency

Inherited Deficiency

Last updated 31 May 2026 · Immunology clinical guideline

📋 Key Information Summary

📋
  • Primary immunodeficiencies (PIDs) are a heterogeneous group of >480 monogenic disorders affecting innate or adaptive immunity, with an estimated prevalence of 1 in 1,200–2,000 Australians.
  • PIDs follow autosomal dominant, autosomal recessive, X-linked, or polygenic inheritance; X-linked conditions disproportionately affect males.
  • The "10 Warning Signs of PID" (Jeffrey Modell Foundation) should be applied in any child or adult with recurrent, severe, or unusual infections.
  • Combined immunodeficiencies (e.g., Severe Combined Immunodeficiency — SCID) are medical emergencies; newborn screening by TREC assay is now routine in Australia.
  • Antibody deficiencies (CVID, XLA) are the most common symptomatic PIDs and present with recurrent sinopulmonary infections from late childhood or early adulthood.
  • Diagnosis requires immunoglobulin quantification, lymphocyte subset analysis, functional immune assays, and increasingly next-generation sequencing (genomic testing).
  • Immunoglobulin replacement therapy (IVIg or SCIg) is the mainstay for antibody-deficient patients and is PBS-authority listed in Australia.
  • Haematopoietic stem cell transplantation (HSCT) is curative for SCID and other severe PIDs and is available at specialised paediatric centres in Sydney, Melbourne, Brisbane, and Perth.
  • Gene therapy is emerging for ADA-SCID, X-linked SCID, and Wiskott–Aldrich syndrome; clinical trials are available in Australia.
  • Genetic counselling is essential for all families with confirmed PIDs; pre-symptomatic diagnosis in subsequent pregnancies can be achieved by cord-blood or prenatal genetic testing.
  • Live vaccines (BCG, OPV, MMR, varicella, yellow fever) are contraindicated in suspected or confirmed severe PIDs until immunological status is clarified.
  • Aboriginal and Torres Strait Islander communities face higher infectious burdens and reduced access to specialist immunology services, necessitating outreach and telehealth pathways.

Introduction & Australian Epidemiology

Primary immunodeficiencies (PIDs) are inborn errors of immunity caused by single-gene (monogenic) or, less commonly, polygenic mutations that compromise one or more arms of the immune system. The International Union of Immunological Societies (IUIS) 2022 classification recognises over 480 distinct disorders, categorised by the affected immune compartment: combined T- and B-cell defects, predominantly antibody deficiencies, phagocyte defects, complement deficiencies, immune dysregulation syndromes, autoinflammatory disorders, and innate immune defects.

In Australia, the Australasian Society of Clinical Immunology and Allergy (ASCIA) and the Australian Institute of Health and Welfare (AIHW) estimate that approximately 25,000–50,000 Australians live with a PID, though many remain undiagnosed. The Australian National PID Registry (managed through ASCIA) has enrolled several thousand patients since its inception. Antibody deficiencies account for approximately 55–65 % of diagnosed PIDs, followed by phagocytic disorders (~15 %), combined immunodeficiencies (~10 %), complement deficiencies (~5 %), and other disorders.

The advent of newborn screening using the T-cell receptor excision circle (TREC) assay, implemented nationally in Australia from 2018–2020, has transformed early detection of SCID and other severe T-cell lymphopenias. This has significantly reduced mortality by enabling timely referral for definitive therapy such as HSCT.

Early recognition and appropriate management of PIDs remain critical, as delayed diagnosis is associated with irreversible organ damage, chronic lung disease (bronchiectasis), and increased mortality. This guideline outlines the genetic mechanisms, classification, diagnostic approach, and treatment strategies for inherited immune deficiencies in the Australian context.

Inherited Deficiency clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — Inherited Deficiency: pathophysiology, clinical clues, diagnosis, imaging, and management.
Inherited Deficiency infographic, full size

Genetic Mechanisms

Understanding the genetic basis of PIDs is essential for accurate diagnosis, prognostication, and family counselling. The following genetic mechanisms underpin the majority of inherited immune deficiencies.

Inheritance Patterns

Pattern Examples Key Features
X-linked recessive XLA (BTK), X-SCID (IL2RG), Wiskott–Aldrich (WAS), CGD (CYBB) Males predominantly affected; carrier females usually asymptomatic; 50 % of sons of carrier mothers affected
Autosomal recessive ADA-SCID, PNP deficiency, Artemis-SCID, RAG1/2 deficiency, MHC II deficiency Both parents carriers; 25 % risk per pregnancy; consanguinity increases risk significantly
Autosomal dominant STAT1 GOF, STAT3 LOF (Hyper-IgE syndrome), CTLA-4 haploinsufficiency 50 % transmission; variable penetrance and expressivity
Somatic (de novo) Activated PI3Kδ syndrome (somatic PIK3CD mutations) Not inherited; present in only a proportion of lymphocytes
Polygenic / complex Selective IgA deficiency, partial complement deficiencies Multiple loci contribute; variable expressivity; may progress to CVID

Molecular Pathways Affected

  • T-cell development: Mutations in IL2RG, JAK3, RAG1/2, ADA, DCLRE1C (Artemis), and IL7RA disrupt thymic T-cell maturation, resulting in severe combined immunodeficiency.
  • B-cell differentiation: BTK mutations prevent pre-B-cell receptor signalling (XLA); defects in ICOS, TACI, BAFF-R, or CD19 impair class-switch recombination and somatic hypermutation (CVID phenocopies).
  • Phagocyte function: NADPH oxidase complex mutations (CYBB, CYBA, NCF1, NCF2, NCF4) cause chronic granulomatous disease (CGD); mutations in ELANE or HAX1 cause severe congenital neutropaenia.
  • Complement cascade: Deficiencies in early classical pathway components (C1q, C2, C4) predispose to immune-complex disease; terminal complement defects (C5–C9) predispose to Neisseria meningitidis infections.
  • Innate signalling: Defects in TLR3 (herpes simplex encephalitis), IFN-γ/IL-12 axis (Mendelian susceptibility to mycobacterial disease), and complement lectin pathway.
⚠️
Consanguinity warning: In communities with higher rates of consanguineous unions, autosomal recessive PIDs are significantly more common. A detailed family pedigree, including consanguinity status, should be obtained for every patient being evaluated for suspected PID.

Types of Deficiency

PIDs are classified according to the IUIS 2022 framework. The following table summarises the major categories with representative Australian-relevant examples.

Combined Immunodeficiencies

Disorder Gene(s) Inheritance Key Features
X-linked SCID IL2RG X-linked Absent T cells, present B cells (T⁻B⁺NK⁻); most common SCID subtype
ADA-SCID ADA AR T⁻B⁻NK⁻; toxic metabolite accumulation; skeletal abnormalities
Artemis-SCID DCLRE1C AR Radiosensitive; T⁻B⁻NK⁺; higher prevalence in some First Nations populations
Omenn syndrome RAG1/2, DCLRE1C AR Erythroderma, lymphadenopathy, hepatosplenomegaly, elevated IgE
MHC II deficiency CIITA, RFXANK, RFX5, RFXAP AR CD4⁺ T-cell lymphopenia; severe diarrhoea and respiratory infections

Predominantly Antibody Deficiencies

Disorder Gene(s) Inheritance Key Features
X-linked agammaglobulinaemia (XLA) BTK X-linked Absent B cells; markedly reduced all immunoglobulin classes; presents 6–12 months
Common variable immunodeficiency (CVID) Often polygenic; ICOS, TACI, BAFF-R in some Variable Most common symptomatic PID in adults; reduced IgG ± IgA/IgM; autoimmunity, granulomata
Selective IgA deficiency Largely unknown Polygenic IgA <0.07 g/L; most common PID overall (~1:300–700); often asymptomatic
Hyper-IgM syndromes CD40LG, CD40, AID, UNG X-linked (CD40LG) or AR Defective class-switch recombination; normal/elevated IgM, low IgG/IgA/IgE; opportunistic infections

Phagocytic Disorders

  • Chronic granulomatous disease (CGD): Defective NADPH oxidase → inability to kill catalase-positive organisms (Staphylococcus aureus, Aspergillus, Serratia, Burkholderia). X-linked (CYBB) ~70 %; autosomal recessive ~30 %. Characterised by granuloma formation, lymphadenitis, liver abscess, and pulmonary aspergillosis.
  • Severe congenital neutropaenia (SCN): ELANE, HAX1, and other gene mutations. ANC persistently <0.2 × 10⁹/L. High risk of bacterial sepsis and myelodysplasia/leukaemia if untreated.
  • Leukocyte adhesion deficiency (LAD) I–III: Impaired neutrophil migration. LAD-I (ITGB2/CD18) most common — delayed umbilical cord separation, poor wound healing, absent pus formation.

Complement Deficiencies

  • Early classical (C1q, C2, C4): Strongly associated with SLE-like illness and immune-complex glomerulonephritis.
  • Terminal complement (C5–C9): Recurrent Neisseria meningitidis infections; meningococcal vaccination essential.
  • Mannose-binding lectin (MBL) deficiency: Common polymorphism (~5 % homozygous); clinical significance debated but may increase infection susceptibility in early childhood.

Immune Dysregulation Syndromes

  • IPEX (FOXP3): X-linked; severe autoimmune enteropathy, eczema, type 1 diabetes, thyroiditis in infancy.
  • IPEX-like (CTLA-4, LRBA, STAT1 GOF): Autoimmune cytopenias, lymphoproliferation, organ-specific autoimmunity.
  • ALPS (FAS, FASLG, CASP10): Defective lymphocyte apoptosis → massive lymphadenopathy, splenomegaly, autoimmune cytopenias, elevated DNT cells.

Autoinflammatory Disorders

  • Cryopyrin-associated periodic syndromes (CAPS): NLRP3 mutations; urticaria-like rash, fever, arthralgia, meningitis. Responsive to IL-1 blockade (anakinra, canakinumab).
  • Familial Mediterranean fever (FMF): MEFV mutations; recurrent febrile serositis; colchicine prophylaxis.
  • TRAPS: TNFRSF1A mutations; prolonged febrile episodes with periorbital oedema and myalgia.

Diagnosis

When to Suspect a PID

The Jeffrey Modell Foundation "10 Warning Signs" remain a useful screening tool. Any patient meeting ≥2 criteria warrants immunological evaluation:

  1. ≥4 new ear infections within 1 year
  2. ≥2 serious sinus infections within 1 year
  3. ≥2 months on antibiotics with little effect
  4. ≥2 pneumonias within 1 year
  5. Failure to thrive or poor growth
  6. Recurrent deep-seated infections (liver/brain abscess, osteomyelitis)
  7. Persistent thrush or fungal skin infection beyond infancy
  8. Need for IV antibiotics to clear infections
  9. ≥2 family members with PID
  10. Features suggestive of immune dysregulation (autoimmune cytopenias, granulomata, severe eczema)
ℹ️
Adult-onset PIDs are not rare. CVID, specific antibody deficiency, and complement deficiency may first present in the 2nd–5th decade. A high index of suspicion is required in adults with recurrent pneumonia, bronchiectasis of unknown cause, or unusual opportunistic infections.

First-Line Investigations (Primary Care)

Available Full blood count with differential MBS Item 65070. Assess lymphocyte, neutrophil, monocyte, and eosinophil counts. Age-specific reference ranges are essential — neonatal lymphocyte counts differ markedly from adults.
Available Quantitative immunoglobulins (IgG, IgA, IgM, IgE) MBS Item 65090. Compare to age-matched normals. IgG subclasses alone are not sufficient for diagnosis of PID.
Available Serum protein electrophoresis MBS Item 65100. Identifies hypogammaglobulinaemia and paraproteins.
Available Liver function tests, renal function, CRP Baseline organ function and inflammatory markers.
Available Chest X-ray Assess thymic shadow (absent thymus in SCID), lymphoid tissue, bronchiectasis.

Second-Line Investigations (Specialist Immunology)

Specialist Lymphocyte subset analysis (CD3, CD4, CD8, CD19, CD16/56) Flow cytometry — available at major hospital laboratories (NSW, VIC, QLD, WA, SA). Essential for SCID screening confirmation and CVID phenotyping.
Specialist Specific antibody responses (pneumococcal serotypes, tetanus, diphtheria) Pre- and post-vaccination titres. Failure to mount protective responses to unconjugated polysaccharide antigens supports specific antibody deficiency.
Specialist Neutrophil oxidative burst (DHR assay) or NBT test Diagnostic for CGD. Available at specialist centres.
Specialist CH50 / AH50 complement functional assays Screen for classical and alternative pathway deficiencies. Low CH50 → individual component quantification (C3, C4, C1q, etc.).
Specialist Lymphocyte proliferation assays (PHA, ConA, anti-CD3) Functional T-cell assessment. Markedly reduced in SCID and combined immunodeficiencies.
Essential Genomic testing (targeted gene panel, WES, or WGS) Genomic testing via state genetics services or national referral (e.g., Melbourne Genomics, Garvan Institute). Essential for molecular confirmation and genetic counselling. MBS-funded under MBS 73298 (WES) for clinical indications.

Newborn Screening — TREC Assay

✅
Australian newborn bloodspot screening now includes TREC assay. Low or absent TREC copies indicate T-cell lymphopenia and trigger immediate recall for confirmatory lymphocyte subset testing and clinical review by a paediatric immunologist. This has reduced SCID mortality to <10 % with early HSCT.

Diagnostic Algorithm

1
Clinical Suspicion
Warning signs, family history, recurrent or severe infections, failure to thrive
2
First-Line Bloods
FBC/diff, immunoglobulins, serum protein electrophoresis, CXR
3
Immunology Referral
Flow cytometry, functional assays, complement, neutrophil studies
4
Genomic Confirmation
Targeted panel or WES/WGS; genotype–phenotype correlation
5
Family Screening & Counselling
Cascade testing, carrier detection, prenatal options

Genetic Counselling & Treatment

Genetic Counselling

All families with a confirmed molecular diagnosis of PID should be referred to a clinical geneticist or genetic counsellor. Key counselling components include:

  • Recurrence risk education: X-linked — 50 % carrier risk for daughters, 50 % affected sons; autosomal recessive — 25 % per pregnancy; autosomal dominant — 50 % with variable penetrance.
  • Carrier testing: Available for X-linked conditions (BTK, IL2RG, WAS) and most autosomal recessive PIDs. Pre-conception carrier screening programmes (e.g., Mackenzie's Mission) are expanding in Australia.
  • Prenatal diagnosis: Chorionic villus sampling (CVS) at 11–13 weeks or amniocentesis at 15–18 weeks for known familial mutations. Non-invasive prenatal testing (NIPT) is not yet standard for PIDs.
  • Preimplantation genetic testing (PGT-M): Available at accredited Australian IVF centres for families with known monogenic PID mutations.
  • Psychosocial support: Referral to patient organisations (IDFA — Immune Deficiencies Foundation of Australia; Jeffrey Modell Foundation ANZ) for peer support and advocacy.

Treatment Overview

Immunoglobulin Replacement Therapy

The cornerstone of management for antibody-deficient patients. Two routes are available in Australia:

💉
Intravenous Immunoglobulin (IVIg)
Intragam® P · Privigen® · Flebogamma®
Adult dose 400–600 mg/kg IV every 3–4 weeks
Paediatric dose 400–600 mg/kg IV every 3–4 weeks
Route / Frequency IV infusion, every 21–28 days in hospital or home infusion programme
Renal adjustment Use sucrose-free preparations; monitor renal function; rate ≤2 mg/kg/min if CKD
PBS status ✔ PBS Authority Required
💉
Subcutaneous Immunoglobulin (SCIg)
Hizentra® · Cuvitru® · Subgam®
Adult dose 100–200 mg/kg SC weekly (or equivalent divided doses)
Paediatric dose 100–200 mg/kg SC weekly
Route / Frequency SC infusion via pump or rapid push; self-administered at home after training
Advantages Fewer systemic reactions; home-based; more stable serum IgG troughs
PBS status ✔ PBS Authority Required
⚠️
IgA-deficient patients: Selective IgA deficiency patients may develop anti-IgA antibodies and are at risk of anaphylaxis with standard Ig preparations. Use IgA-depleted products (e.g., Gammagard Liquid SD/IgA <1 µg/mL) or SCIg. Always check IgA level before initiating immunoglobulin therapy.

Antibiotic Prophylaxis

  • Co-trimoxazole (trimethoprim–sulfamethoxazole) 480 mg PO daily (paediatric: 5–6 mg/kg/day trimethoprim component) — first-line for CGD prophylaxis and adjunctive in antibody deficiency. PBS: General Benefit.
  • Azithromycin 250 mg PO three times weekly (paediatric: 5–10 mg/kg/week) — alternative or adjunct for CGD and bronchiectasis prophylaxis in CVID. PBS: Authority Required for prophylaxis indications.
  • Amoxicillin 500 mg PO daily or cephalexin 500 mg PO daily — adjunctive in specific antibody deficiency with recurrent URTI. PBS: General Benefit.

Definitive Therapies

Therapy Indication Availability in Australia
Haematopoietic stem cell transplant (HSCT) SCID (all forms), WAS, CGD (severe), HLH, IPEX Sydney Children's Hospital, Royal Children's Hospital Melbourne, Queensland Children's Hospital, Perth Children's Hospital
Gene therapy ADA-SCID (Strimvelis® / OTL-101), X-SCID, WAS Clinical trials at RCH Melbourne; some patients referred overseas
Enzyme replacement (PEG-ADA) ADA-SCID (bridge to HSCT or if HSCT not feasible) PBS Authority Required; administered IV twice weekly
Granulocyte colony-stimulating factor (G-CSF) Severe congenital neutropaenia (ELANE, HAX1) Filgrastim (Neupogen®) PBS General Benefit; pegfilgrastim available
Biologic therapies (IL-1, IL-6, JAK inhibitors) Autoinflammatory disorders (CAPS, TRAPS), immune dysregulation Anakinra (Kineret®) PBS Authority for CAPS; tocilizumab, baricitinib on case-by-case

Infection Prevention & Vaccination

  • All inactivated vaccines are safe and recommended (including COVID-19, influenza, pneumococcal conjugate, meningococcal B and ACWY).
  • Live vaccines are CONTRAINDICATED in SCID, combined immunodeficiencies, symptomatic XLA/CVID, and phagocytic disorders until immunological clearance is obtained.
  • BCG: Contraindicated in all severe PIDs. Neonates from high-risk TB settings should have immune evaluation before BCG administration.
  • MMR and varicella vaccines: May be safe in mild/moderate PIDs (e.g., selective IgA deficiency, specific antibody deficiency) — specialist advice required.
  • Household contacts of PID patients should be fully vaccinated, including annual influenza vaccination.

Monitoring

Every visit Infection frequency log, lung function (spirometry), growth monitoring in children
3–6 monthly Serum IgG trough level (target ≥5 g/L for most antibody deficiencies; individualise); CBC, LFT, renal function
Annually HRCT chest if bronchiectasis suspected; liver ultrasound (CGD); lymphocyte subsets; autoimmune screen if immune dysregulation phenotype
As indicated Genetic re-analysis (reclassification of VUS), functional immune reconstitution post-HSCT, donor chimerism

Special Populations

👶 Paediatrics
SCID newborn screening: Low TREC result → immediate recall, avoid live vaccines, lymphocyte subsets within 72 hours. Refer to tertiary paediatric immunology.
Immunoglobulin dosing: Weight-based; infants require higher per-kg doses due to larger volume of distribution and faster catabolism.
Growth & development: Chronic infections impair growth; monitor height, weight, developmental milestones, and school attendance.
🤰 Pregnancy
IVIg/SCIg: Safe in pregnancy; continue at standard doses. Immunoglobulin crosses the placenta in the third trimester — beneficial for foetus.
Live vaccines: Contraindicated in pregnant PID patients.
Genetic counselling: Offer prenatal genetic testing for known familial mutations; discuss PGT-M if available.
👴 Elderly
Secondary hypogammaglobulinaemia: Exclude CLL, myeloma, nephrotic syndrome, immunosuppressive medications before diagnosing late-onset CVID.
Infusion reactions: More common with IVIg in elderly; consider SCIg or slower infusion rates.
Vaccination: Ensure pneumococcal (PCV13 then PPSV23) and influenza vaccination are up to date.
🫘 Renal Impairment
IVIg selection: Avoid sucrose-containing preparations (risk of osmotic nephrosis). Use albumin-stabilised or proline-stabilised products.
Dose adjustment: Reduce infusion rate to ≤2 mg/kg/min; monitor creatinine and urine output post-infusion.
🫁 Hepatic Impairment
IgG catabolism: Severe liver disease may alter IgG half-life; monitor trough levels closely.
Coagulation: IVIg products contain variable sodium and may affect coagulation — use cautiously in hepatic coagulopathy.
🦠 Immunocompromised
Post-HSCT: Continue immunoglobulin replacement until immune reconstitution confirmed (B-cell engraftment, specific antibody responses).
Biologic therapies: Anti-TNF agents, rituximab may cause secondary immunodeficiency — monitor immunoglobulin levels.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Higher infectious disease burden
ATSI children experience significantly higher rates of otitis media, pneumonia, bronchiectasis, and skin infections. These may be the presenting features of an underlying PID but are often attributed solely to environmental factors, leading to diagnostic delay. A lower threshold for immunological investigation is warranted.
Specific genetic variants
Certain autosomal recessive PIDs may be enriched in communities with founder mutations or higher rates of consanguinity. Artemis-SCID (DCLRE1C) and other DNA repair defects have been reported in First Nations populations. Genomic databases including the A珖ANGA project aim to improve variant interpretation for ATSI individuals.
Access to specialist services
Clinical immunology services are concentrated in metropolitan centres. Remote and very remote communities face significant barriers to specialist assessment, flow cytometry, and genomic testing. Telehealth immunology consultations, available via Medicare rebate, are essential for equitable access.
Immunoglobulin therapy access
SCIg self-administration is particularly valuable in remote settings where regular hospital IVIg infusions are impractical. Training programmes for community health nurses and patient self-management have been implemented in NT and QLD.
Vaccination considerations
BCG vaccination is routine in some ATSI neonatal programmes. In communities where BCG is administered at birth, the possibility of SCID must be considered — BCG-osis (disseminated BCG infection) is a recognised complication in undiagnosed SCID. Coordination with newborn screening TREC results is critical.
Cultural safety
Engagement with Aboriginal Health Workers and Liaison Officers is essential. Genetic counselling must be culturally appropriate, acknowledging kinship structures and community decision-making processes. Information should be provided in plain language and, where possible, in local language.

📚 References

  1. 1. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–1507.
  2. 2. Australasian Society of Clinical Immunology and Allergy (ASCIA). Primary immunodeficiency (PID) guide for healthcare professionals. ASCIA; 2024. Available at: https://www.allergy.org.au
  3. 3. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.
  4. 4. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–738.
  5. 5. Australian Government Department of Health and Aged Care. Newborn bloodspot screening national policy framework. Commonwealth of Australia; 2023.
  6. 6. Immune Deficiencies Foundation of Australia (IDFA). Living with primary immunodeficiency in Australia. IDFA; 2023. Available at: https://idfa.org.au
  7. 7. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–1205.
  8. 8. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46.
  9. 9. Australian Institute of Health and Welfare (AIHW). Chronic respiratory conditions: bronchiectasis in Aboriginal and Torres Strait Islander people. AIHW; 2023. Cat. no. PHE 312.
  10. 10. Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2017;37(3):291–297.
  11. 11. National Health and Medical Research Council (NHMRC). Australian guidelines for the clinical care of people with cystic fibrosis 2023 (immunological considerations). NHMRC; 2023.
  12. 12. Mackenzie's Mission. Reproductive genetic carrier screening programme. Australian Genomics; 2023. Available at: https://www.mackenziesmission.org.au
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).